A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Inclusion Criteria: * Histologically proven diagnosis of advanced or metastatic solid tumors for whom either refractory to standard therapy exists, or for whom treatment with an investigational agent alone or in combination with docetaxel, paclitaxel, carboplatin, or paclitaxel plus carboplatin is appropriate; * ANC≥ 1.5 x 109/L; * Hgb ≥ 9.0 g/L; * PLT ≥ 100,000/mm3; * Total bilirubin ≤ 1.5; * Willing and able to remain in the clinic for at least 4 days Exclusion Criteria: * Patients with CNS and/or leptomeningeal disease metastases allowed on the study unless asymptomatic and not requiring corticosteroid therapy. Patients having any clinical signs of CNS metastases must have a CT or MRI of the brain performed to rule out CNS metastases in order to be eligible for study participation. Patients who have had brain metastases surgically removed or irradiated with no residual disease confirmed by imaging are allowed; * Patients unable to undergo intravenous infusion; * Patients with a Baseline 12-lead EGC QTc of \>450 msec; * Radiotherapy in less than two (2) weeks prior to study entry; * A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits Other protocol-defined inclusion/exclusion criteria may apply